Accreditation/Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC designates this live activity for a maximum of 22.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Commercial SupportThis activity is supported by educational grants from Amgen Inc., Astellas, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Biodesix Inc., Bristol-Myers Squibb, Celgene Corporation, Clovis Oncology, Genentech, Lilly, and Novartis Pharmaceuticals Corporation.
For further information concerning Lilly grant funding visit www.lillygrantoffice.com.
16th Annual International Lung Cancer Congress®
July 30 - August 1, 2015
Hyatt Regency Huntington Beach
Huntington Beach, CA
OverviewThe International Lung Cancer Congress® provides current, practical information on the management of lung cancer, as well as a look at the novel agents and strategies that will shape the future of lung cancer therapy. Leading international and national faculty will address critical topics in lung cancer staging, personalized therapy, and the latest clinical data impacting the treatment of lung cancer. Cutting-edge lectures, panel discussions, multidisciplinary tumor boards, and interactive question-and-answer sessions will provide a unique opportunity for participants to engage with faculty as they share their perspectives and personal experiences on the clinical challenges and ongoing controversies in lung cancer management. The meeting also includes a recurring session that highlights clinical research activity of Cooperative Groups in the United States, Europe, and Asia.
A fantastic segment ran on KABC Los Angeles last night entitled "Lung Cancer Strikes Younger Demographic." It was filmed last week at PER®'s International Lung Cancer Congress® and featured interviews with Dr. Barbara Gitlitz, Bonnie J Addario, and 28 year old lung cancer survivor Emily Bennett Taylor.
Click here to watch the video.
Target AudienceThis educational activity is directed toward medical, surgical and radiation oncologists interested in the treatment of patients with lung cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers and other healthcare professionals interested in the treatment of lung cancer are also invited to attend.
At the conclusion of this activity, participants should be better prepared to:
- Outline best practices for diagnosis and staging of lung cancer
- Summarize appropriate biomarker testing/re-testing strategies to be applied based upon patient and disease characteristics
- Discuss treatment strategies for early-stage and locally advanced lung cancer
- Describe strategies to optimize treatment plans in patients with lung cancer, considering factors such as efficacy of a drug in different settings, prior therapies, existing comorbidities, and disease characteristics
- Evaluate data on new agents and approaches in development for lung cancer
- Review recent data on immune-checkpoint inhibition with anti-PD-1, anti-PD-L1, and anti-CTLA-4 blockade
- Assess how emerging data on the use of molecularly targeted agents can be used to improve the treatment of patients with NSCLC
- Identify appropriate clinical trials examining novel agents that are designed to benefit patients with lung cancer
David R. Gandara, MD
Professor of Medicine
Division of Hematology/Oncology
Director, Thoracic Oncology Program
Senior Advisor to the Director
UC Davis Comprehensive Cancer Center
Roy S. Herbst, MD, PhD
Ensign Professor of Medicine (Medical Oncology)
Professor of Pharmacology
Chief of Medical Oncology
Associate Director for Translational Research
Yale Cancer Center
Yale School of Medicine
New Haven, CT
Accreditation/Designation of Credit Statement
Physicians' Education Resource®, LLC, (PER®) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physician's Education Resource®, LLC designates this live activity for a maximum of 22.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Commercial Support
This activity is supported by educational grants from Amgen Inc., Astellas, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Biodesix Inc., Bristol-Myers Squibb, Celgene Corporation, Clovis Oncology, Genentech, Lilly, and Novartis Pharmaceuticals Corporation.
For further information concerning Lilly grant funding visit www.lillygrantoffice.com.
PER® also gratefully acknowledges the Bonnie J. Addario Lung Cancer Foundation and the International Association for the Study of Lung Cancer for their support of this CME activity.
Disclosure Policy and Resolution of Conflicts of Interest (COI)
As a sponsor accredited by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a COI.Additionally, PER® is required by ACCME to resolve all COI. We have identified and resolved all COI prior to the start of this activity by using a multistep process.
Faculty and Staff Disclosures
The following individuals have no relevant financial relationships with commercial interests to disclose:
Friedrich Knollmann, MD, PhD; Ken Yoneda, MD; Daniel Lieber, MD; Philip Mack, PhD; Ravi Salgia, MD, PhD
The staff of PER®: David Lee, PhD; Ann C. Lichti, CHCP; and Michael Perlmutter, MS, PharmD
The following individuals have relevant financial relationships with commercial interests to disclose:
Paul Baas, MD, PhD - Grant Research Support: Bristol-Myers Squibb, MSD Pharmaceuticals; Consultant: Verastem, MSD Pharmaceuticals, Bristol-Myers Squibb, AstraZeneca, Pfizer; Lyudmila Bazhenova, MD - Consultant: Clovis Pharmaceuticals, Genoptix, Boehringer Ingelheim, Seattle Genetics; Speakers Bureau: Genentech, Pfizer; Shareholder: Epic Sciences; Paul Bunn, Jr, MD - Grant Research Support: AstraZeneca, Eisai; Consultant: AstraZeneca, Amgen, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Daiichi, Eisai, Genentech, Lilly, Merck, Novartis, Clovis; Walter Curran, Jr, MD - Consultant: Bristol-Myers Squibb, AstraZeneca; Shareholder: NantHealth; Roy Decker, MD, PhD - Grant Research Support: Merck & Co, Inc; 21st Century Oncology; Consultant: AMAG Pharmaceuticals, Leidos Biomedical Research, Inc.; Shareholder: Bristol-Myers Squibb; David Gandara, MD - Grant Research Support: Abbott, Bristol-Myers Squibb, ImClone, Genentech, Lilly, Merck, Novartis, Pfizer; Consultant: Amgen, AstraZeneca, Boehringer Ingelheim, BioMarin, Bristol-Myers Squibb, Celgene, Genentech, GlaxoSmithKline, Merck, Novartis, Pfizer, sanofi-aventis, Response Genetics Inc., Synta Pharmaceuticals; Barabara Gitlitz, MD - Speakers' Bureau: Genentech, Eli Lilly; Glenwood D. Goss, MD, BCh, FCP(SA), FRCPC - Grant Research Support: AstraZeneca; Advisory Board Honoraria: Bristol-Myers Squibb, AstraZeneca, Boehringer Ingelheim, Roche, Pfizer; Roy Herbst, MD, PhD - Grant Research Support: Genentech; Consultant: Ariad Pharmaceuticals, Eli Lilly, Genentech/Roche, Gilead, Merck, Pfizer; Scientific Advisory Boards: Biothera, Diatech, Kolltan, N of 1; Fred Hirsch, MD, PhD - Grant/Research Support: Celgene, Genentech, Ventana, Amgen, ImClone/Lilly; Consultant: Genentech/Roche, Pfizer, Novartis, Celgene, Biodesix, Biothera, Synta; Karen Kelly, MD - Grant Research Support: Millennium, Novartis, Proacta, Lilly, Synta, EMD Serono, Genentech; Consultant: Clovis, Genentech, Lilly, Transgene, Synta, AstraZeneca; Corey Langer, MD, FACP - Grant Research Support: Merck, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis, AstraZeneca, Advantagene, Inovio Pharmaceuticals, Nektar, Genentech/Roche, GlaxoSmithKline; Consultant: Abbott, Clovis, Lilly, Genentech/Roche, Boehringer Ingelheim, AstraZeneca/MedImmune, Pfizer; Data and Safety Monitoring Committee, Lilly, Amgen, Peregrine Pharmaceuticals, Synta; Primo Lara, Jr, MD Grant/Research Support: Millennium, Aragon, Janssen, Polaris, OncoGeneX, GlaxoSmithKline, Genentech; Consultant: Janssen, Clovis, Astex, USOS, Exelixis, Immunojen, Pfizer, Teva, Medivation, Novartis, Halozyme, Sanofi, LPath, Lilly; Tony Mok, MD - Consultant: AstraZeneca, Roche/Genentech, Pfizer, Eli Lilly, Boehringer Ingelheim, Merck Serono, MSD, Janssen, Clovis Oncology, BioMarin, GlaxoSmithKline, Novartis, SFJ Pharmaceuticals, ACEA Biosciences, Inc; Speakers' Bureau: AstraZeneca, Roche/Genentech, Pfizer, Eli Lilly, Boehringer Ingelheim, MSD, Amgen, Janssen, Clovis Oncology, GlaxoSmithKline, Novartis; Shareholder: Sanomics Limited ; Sai-Hong Ignatius Ou, MD, PhD - Grant Research Support: Pfizer, Roche, AstraZeneca, Clovis, Ariad Pharmaceuticals, Ignyta, GlaxoSmithKline; Consultant: Pfizer, Roche; Speakers' Bureau: Roche, Boehringer Ingelheim; Scientific Advisor: Ignyta; Harvey Pass, MD - Grant Research Support: National Cancer Institute, Technion, Centers for Disease Control and Prevention; Consultant: Visiongate; Suresh Ramalingam, MD - Consultant: AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Lilly, Genentech, Novartis; Jonathan Riess, MD, MS - Grant Research Support: Merck, Millennium, Onconova Therapeutics, Novartis; Consultant: Celgene; Honoraria: Genentech; Naiyer Rizvi, MD - Consultant: Merck, Roche, Bristol-Myers Squibb, AstraZeneca; Jack Roth, MD, FACS - Grant Research Support: Varian; Consultant: Genprex; Shareholder: Genprex; Patents: Genprex (all held by the University of Texas); Giorgio Scagliotti, MD, PhD - Consultant: Lilly; Speakers' Bureau: Eli Lilly, AstraZeneca, Pfizer, Roche, Clovis Oncology; Everett Vokes, MD - Consultant: AbbVie, AstraZeneca, Boehringer Ingelheim, Celgene, Clovis, Eisai, Eli Lilly, GeneCentric, Genentech, Merck, Synta, Transgene, VentiRx; Heather Wakelee, MD - Grant Research Support: Novartis, Bristol-Myers Squibb, Clovis, Xcovery, Celgene, Roche/Genentech, MedImmune, Pfizer, Lilly; Consultant: Peregrine, Novartis; Ignacio Wistuba, MD - Grant Research Support: CPRIT, Asuragen, DoD, National Institutes of Health/National Cancer Institute, LUNGevity Foundation, Medical Research Foundation, Genentech, University of Michigan; Consultant: Genentech/Roche, Boehringer Ingelheim, National Comprehensive Cancer Network, Bristol-Myers Squibb; Sue Yom, MD, PhD - Grant Research Support: Genentech; Advisory Board Member: DARA BioSciences, Inc.
Information accurate at the time of posting.
Off-Label Disclosure and Disclaimer
This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only, and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient's medical condition.
The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any of the companies that provided commercial support for this activity.
Physician Payments Sunshine Act
PER® complies with the Physician Payments Sunshine Act as a part of the Affordable Care Act (ACA). Accordingly, we may be required to collect information on transfers of value provided to any covered recipient under the ACA.
You must be logged in to PER to register for this meeting
Or Register for PER now
In case of onsite emergency:
Assumption of Risk and Waiver of Liability Relating to Coronavirus/COVID-19
I understand that the hazards of the novel coronavirus ("COVID-19") and have reviewed the Centers for Disease Control and Prevention ("CDC") current guidelines in regards to COVID-19. I acknowledge that while Physicians' Education Resource, LLC ("PER") ("Company") has put in place preventive measures to reduce the spread of COVID-19, Company cannot guarantee that I or anyone else will not become infected with COVID-19. I attest that if within the fourteen (14) days prior to the event, I am experiencing any symptoms of COVID-19, I will not attend the Activities. I shall follow any safety, social distancing, masking, and hygiene protocols that have been implemented at the Activities, including providing proof at check in of being 2 weeks removed from receiving a full COVID-19 vaccination or results from a negative COVID-19 viral test taken no more than 3 days prior to the program.
I hereby willingly and voluntarily choose to attend this PER event and related activities ("Activity"). I acknowledge and fully assume the risk and hazards of exposure to COVID-19 and that such exposure or infection may result in personal injury, illness, permanent disability, and death to myself, my spouse, children, unborn child, or relatives. I acknowledge that Company may share my personal information for the purpose of contact tracing if the need arises, and I hereby consent to the release of my personal information for such purpose. I hereby release covenant not to sue, forever discharge, and hold harmless Company and its affiliates from all liability claims and demands of whatever kind of nature, either in law or in equity, which arise or may hereafter arise from participating in the Activities. I assume all risks of losses, damages, or injuries that may be sustained while participating in the Activity. I understand and agree that this release includes any Claims based on the actions, omissions, or negligence of the venue, employees, vendors, agents, and representatives, whether a COVID-19 infection occurs before, during, or after participation in the Activity.
* By checking this box, you have read and understand the above and agree to its terms.